Sean van Diepen
A5057325715- Cardiac Arrest and Resuscitation
- Mechanical Circulatory Support Devices
- Sepsis Diagnosis and Treatment
- Cardiac Structural Anomalies and Repair
- Cardiac, Anesthesia and Surgical Outcomes
- Heart Failure Treatment and Management
- Acute Myocardial Infarction Research
- Respiratory Support and Mechanisms
- Intensive Care Unit Cognitive Disorders
- Emergency and Acute Care Studies
- Trauma and Emergency Care Studies
- Hemodynamic Monitoring and Therapy
- Pulmonary Hypertension Research and Treatments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 Clinical Research Studies
- Cardiovascular and exercise physiology
- Cardiac Health and Mental Health
- Cardiac Valve Diseases and Treatments
- Heart Rate Variability and Autonomic Control
- Venous Thromboembolism Diagnosis and Management
- Acute Kidney Injury Research
University of Alberta
2016-2025
Canadian VIGOUR Centre
2016-2025
Alberta Hospital Edmonton
2016-2025
University of Alberta Hospital
2016-2025
St. Michael's Hospital
2013-2025
University of Toronto
2013-2025
University of British Columbia
2017-2025
Clinical Research Institute
2012-2025
St. Paul's Hospital
2025
Duke University
2012-2025
Abstract Background The outcome of cardiogenic shock complicating myocardial infarction has not appreciably changed in the last 30 years despite development various percutaneous mechanical circulatory support options. It is clear that there are varying degrees but no robust classification scheme to categorize this disease state. Methods A multidisciplinary group experts convened by Society for Cardiovascular Angiography and Interventions was assembled derive a proposed schema shock....
AIM: The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new evidence since “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Diagnosis Stable Ischemic Heart corresponding “2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update Disease.” METHODS: A comprehensive literature search was conducted from September 2021 May 2022. Clinical studies, systematic reviews meta-analyses, other on human participants were identified...
Background Clinical investigations of shock in cardiac intensive care units (CICUs) have primarily focused on acute myocardial infarction (AMI) complicated by cardiogenic (AMICS). Few studies evaluated the full spectrum contemporary CICUs. Methods and Results The Critical Care Cardiology Trials Network is a multicenter network advanced CICUs North America. Anytime between September 2017 2018, each center (n=16) contributed 2-month snap-shot all consecutive medical admissions to CICU. Data...
Levosimendan is an inotropic agent that has been shown in small studies to prevent or treat the low cardiac output syndrome after surgery.In a multicenter, randomized, placebo-controlled, phase 3 trial, we evaluated efficacy and safety of levosimendan patients with left ventricular ejection fraction 35% less who were undergoing surgery use cardiopulmonary bypass. Patients randomly assigned receive either intravenous (at dose 0.2 μg per kilogram body weight minute for 1 hour, followed by 0.1...
Although previous studies have shown marked variation in out-of-hospital cardiac arrest survival across US regions, factors underlying this remain incompletely explained. Using data from the Cardiac Arrest Registry to Enhance Survival, we identified 96 662 adult patients with 132 counties. We used hierarchical regression models examine county-level rates of and functional recovery (defined as Cerebral Performance Category score 1 or 2) examined contribution demographics, characteristics,...
Single-center and claims-based studies have described substantial changes in the landscape of care cardiac intensive unit (CICU). Professional societies recommended research to guide evidence-based CICU redesigns.To characterize patients admitted contemporary, advanced CICUs.This study established Critical Care Cardiology Trials Network (CCCTN), an investigator-initiated multicenter network 16 advanced, tertiary CICUs United States Canada. For 2 months each CICU, data for consecutive...
Platelets represent a potential therapeutic target for improved clinical outcomes in patients with COVID-19.
The efficacy and safety of prophylactic full-dose anticoagulation antiplatelet therapy in critically ill COVID-19 patients remain uncertain.COVID-PACT (Prevention Arteriovenous Thrombotic Events Critically-ill Patients Trial) was a multicenter, 2×2 factorial, open-label, randomized-controlled trial with blinded end point adjudication intensive care unit-level COVID-19. were randomly assigned to strategy or standard-dose anticoagulation. Absent an indication for therapy, additionally either...
Cardiogenic shock secondary to acute myocardial infarction (AMI-CS) is associated with substantial short-term mortality; however, there are limited data on long-term outcomes and trends.This study sought examine of AMI-CS patients.This was a population-based, retrospective cohort in Ontario, Canada critically ill adult patients who were admitted hospitals between April 1, 2009 March 31, 2019. Outcome captured using linked health administrative databases.A total 9,789 consecutive from 135...
Treatment recommendations for the same condition from different guideline bodies often disagree, even when randomized controlled trial (RCT) evidence is cited. Guideline appraisal tools focus on methodology and quality of reporting, but not nature supporting evidence. This study was done to evaluate (based consideration its internal validity, clinical relevance, applicability) underlying therapy in evidence-based practice guidelines.A cross-sectional analysis cardiovascular risk management...
Background— The postoperative risks for patients with coronary artery disease (CAD) undergoing noncardiac surgery are well described. However, the of in heart failure (HF) and atrial fibrillation (AF) less known. purpose this study is to compare mortality HF, AF, or CAD major minor surgery. Methods Results— Population-based data were used create 4 cohorts consecutive either nonischemic HF (NIHF; n=7700), ischemic (IHF; n=12 249), (n=13 786), AF (n=4312) who underwent between April 1, 1999,...
We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in Apixaban for Reduction Stroke Other Thromboembolic Events Atrial Fibrillation Trial (ARISTOTLE), as well effect apixaban versus warfarin.The a number outcomes, including composite SSE death (to take account competing risks) SSE, major bleeding, (net clinical benefit) were calculated 3 patient groups: (1) no HF/no LVSD (n=8728), (2) (n=3207), (3)...